The loss of organs was mainly due to chronic nephropathy or death with a functioning kidney. Background. With a few exceptions, most published studies do not show an influence of antibodies to the Conclusion. The presence of hepatitis C antibodies, before or after transplantation, is associated with a hepatitis C virus (HCV ) on the success of a kidney transplant.
and/or after the transplant were considered to be HCV Introduction positive (HCV+).
Results. The HCV+ patients had more time in dialysis
The relationship between hepatitis C and kidney transand a greater number of transfusions, hyperimmunized plant survival is far from being clarified [1] . Most of cases, and re-transplants. The evolution in the first the studies published [2] [3] [4] [5] [6] [7] [8] [9] have not established a post-transplant year was similar in both groups, but significant influence of the hepatitis C antibody carrier afterwards, the HCV+ patients had proteinuria more status (HCV+) on recipient or kidney survival. often as well as worse kidney function. The survival However, there are studies that indicate otherwise rate of the graft was significantly less in the HCV+ [10] [11] [12] [13] . Pereira et al. [14] demonstrated that precases: 90.6, 68.3 and 51.0% at respectively 1, 5 and 10 transplant HCV+ recipients had a worse survival, and years, compared with 91.5, 84.7 and 66.5% in HCV− Legendre and colleagues [15] found that both HCV+ patients (P<0.01). The patient survival rate was: 96. 4 , recipients and their grafts had poorer long-term out-87.0, and 71.9% in the HCV+ patients at 1, 5, and 10 comes. The aim of the present study is to investigate years, compared with 98.2, 96.0 and 90.0% in the the influence of HCV antibodies in a group of patients HCV− cases respectively (P<0.01). The differences initially treated with a quadruple immunosuppressive remained the same in stratified studies according to therapy using antilymphocyte globulin. time spent in dialysis or pre/post-transplant evolution of HCV antibodies, even when immunologically highrisk patients were excluded. In multivariant analysis, Subjects and methods the presence of HCV antibodies acted as a independent prognostic factor for the survival of the kidney and All patients in our centre with an allograft transplant and the patient: 3.0 (1.8-5.0) and 3.1 (1.2-7.8) odds-ratio undergoing induction therapy with antilymphocyte globulins (95% of the confidence interval ), respectively. The were studied. A total of 335 cases were included between main cause of death among HCV+ patients was January 1986 and February 1997. cardiovascular; there was no apparent increase in morInitial immunosuppressive therapy consisted of steroids, tality rate due to infections or chronic liver disease. azathioprine, and antilymphocyte globulins. Once graft function was verified, oral cyclosporin was progressively introduced. The mean length of therapy with globulins was 9.7 days and cyclosporin was introduced on an average of 3.7 of steroids, azathioprine (1-2 mg/kg) and cyclosporin. (HCV−). As generally found in other studies, the Azathioprine was withdrawn in certain cases, mainly because HCV+ patients have had longer treatment with diaof leucopenia or liver disorders. Acute rejection was dia-lysis, a greater number of transfusions and gnosed by biopsy or clinically after a positive response to re-transplants and, consequently, a greater proportion anti-rejection therapy. Graft rejections were treated with of these patients have a high degree of anti-HLA steroid bolus and rescue therapy with anti-thymocyte globuimmunization. There were no differences in the tech- A mean follow-up period of almost 5 years ( Table 3) samples. The pre-transplant determination was available in revealed similar initial functional course in relation to 300 cases and the post-transplant determination in 291 the incidence of tubular necrosis and renal function, patients. Altogether, the pre-and/or post-transplant antibody status was determined in 320 patients (95.5%). The 15 cases no significant difference in the incidence of acute omitted corresponded to deaths or early failures for which rejection, a greater frequency of significant proteinuria pre-transplant samples were not preserved. Of the 271 cases after the first year, worse middle-term kidney function with the pre-and post-transplant determinations, 73% were (significant after the 3rd year), and a greater incidence negative pre-and post-transplant, 2% changed from positive of abnormal liver biochemistry. Remarkably, the incid- There were no significant differences in the immunotransplant (235 cases). Because of the limited correlation suppressive treatment given to both groups, although found between liver chemistry and the severity of histological the number of cases in which azathioprine was withdamage, we decided to classify a case with pre-transplant drawn was greater in the HCV+ group (20.5% vs clinical liver disease as any patient with a past history of 13.5% for the HCV− group).
abnormal liver enzymes (transaminase and/or gammaglutamyl transpeptidase) of any degree, continuous or intermittent, but lasting longer than 6 months. The same criteria were applied for the presence or absence of post-transplant Survival clinical liver disease.
The comparison of variables between the groups was done For all of the 335 patients treated with the quadruple by applying the x2 test (Pearson), the Mann-Whitney's test therapy (including the 15 cases without a determination and Student's t-test. Survival was studied using the of anti-HCV antibodies), graft survival was 87.5 and Kaplan-Meier method, and comparisons made with the log-58% at the end of the 1st and 10th year respectively. rank method. With reference to organ survival, death with a functioning kidney was considered as a failure. In addition, Patient survival was 96.5 and 81.2% for the same a separate estimation of the graft survival curve was done, periods.
excluding those cases of death with a functioning kidney. In Graft survival is significantly lower in the HCV+ order to estimate recipient survival, patient follow-up was patients, being 90.6, 68.3 and 51.0%, at 1, 5 and 10 prolonged for 4 months after definitive graft failure and shift years, compared to the HCV− patients, with 91.5, are similar for both groups ( Figures 1 and 2 ) during the first 2 or 3 years, with differences appearing at a Results relatively late stage of the post-operative period. Table 4 shows the causes of death and kidney loss Characteristics and course of the patients for each group. It should be pointed out that in the HCV+ group only two patients died of liver failure In Table 1 we compare the characteristics of the HCV+ patients with the constantly negative cases directly, with cardiovascular pathology being the main cause of death. The incidence of lethal infections in (ii) Exclusion of cases with a high immunological risk (re-transplants and hyperimmunized prethis small group does not seem to be greater compared to the HCV− patients. The HCV+ patients lost the transplant). The same conclusions could be drawn for grafts (P=0.008) and recipients (P=0.029). organ mainly due to chronic transplant dysfunction (principally chronic rejection, although biopsy conGraft and patient survival were similar between the pre-transplant HCV+ cases and the assumed seroconfirmation was not available in all cases) and because of death with a functioning kidney. On the other hand, versions, which were lower than for the HCV− cases.
Considering all the patients, there was no difference proportionally fewer kidneys were lost due to uncontrolled acute rejection in the HCV+ group than in the in survival with respect to time on dialysis above or below the median. At both levels of dialysis time, HCV− group.
In order to avoid the bias introduced by the great middle-term graft and patient survival was lower for the HCV+ patients. heterogeneity between both groups, the following verifications were carried out in the univariate analysis:
In the multivariate analysis of graft survival, the statistically significant independent risk factors (odds (i) Repetition of the comparisons after excluding cases with survival less than 6 months (99.5% with ratio with a 95% confidence interval >1, P<0.05)
were: donor greater than 50 years of age, brain death known anti-HCV status). The differences for graft (P= 0.003) and patient (P=0.028) survival remained.
due to a cerebrovascular accident, female donor, recipi- ent with a systemic disorder or diabetes, the number Significant independent risk factors for patient survival were: brain death by cerebrovascular accident, of HLA mismatches, and an HCV+ status. This last carried a relative risk of 3.0 (95% CI 1.8-5.0). In female donor, currently hyperimmunized recipient, number of HLA mismatches, and an HCV+ status previous analyses (not included in the final model ), the following factors were close to statistical signific-(relative risk of 3.1, with a CI of 1.2-7.8). Factors that narrowly failed to reach statistical significance were ance (P of 0.057-0.12): re-transplant, current hyperimmunization, male recipient, and recipient age greater recipient age (0.06), male gender of the recipient, and re-transplant (not included in the final model ). Again, than 50 years. Neither the presence of pre-transplant clinical liver disease, the time of dialysis nor the year the time of dialysis and the pre-transplant clinical liver disease seem to lack influence. Considering the limited of transplantation act as independent factors. the magnitude of the viral load, the predominant HCV Death with functioning kidney 9 (21) 8 (26) genotype in the area, the number of transfusions, or Other 3 (7) 2 (6) the immunosuppressive therapy. With reference to this last factor, the use of globulins has been directly related Percentages in parentheses.
to the course of liver disease. It should be emphasized that both H. Necker's group and ours generally apply number of events, a phenomenon of overfitting could induction therapy with antilymphocyte antibodies, take place in a model with so many factors. However, which could lead to especially active viral replication in different models with a smaller number of factors during the early course of the transplant. Nevertheless, (2-3), it was always possible to include an HCV+ the quadruple therapy has not been associated with a status as an independent risk factor.
high incidence of cytomegalovirus infection or lymphomas in our study, two conditions that suggest over-immunosuppression.
Discussion
The influence of HCV on organ survival could be mediated by various mechanisms (besides an increase in losses due to death with a functioning kidney). Most of the studies published report no differences in kidney transplant survival with respect to hepatitis C Hepatitis C can cause de novo glomerulopathies, as has been clearly demonstrated for membranoprolifera- [2] [3] [4] [5] [6] [7] [8] [9] . Some of these studies have a low number of patients or a very short post-transplant follow-up tive glomerulonephritis [17] and suggested for membranous glomerulopathy [18, 19] . A greater incidence period, which could affect the statistical power for demonstrating differences between the groups. of acute rejection [4] and proteinuria [9] , both traditionally associated with a greater frequency of chronic However, extensive studies such as those of Roth et al. [4] , Orloff et al. [5] and others, do not share these transplant nephropathy, has been reported. Cosio et al. [20] recently described a high incidence of renal vasculimitations and do not document variations in survival (although in certain cases there is a greater frequency lar lesions in HCV+ transplant patients by an as yet unknown mechanism. In the absence of renal biopsy, of infection and rejection in HCV+ patients). On the other hand, Pereira et al. [14] encounters greater we cannot dismiss the possibility of de novo glomerulopathy, clinically indistinguishable from the glomermortality in the pre-transplant HCV+ recipients compared to HCV− patients due to infections and liver ulopathy of chronic rejection. A reduction in immunosuppressive therapy, especially the withdrawal of azadisease. These results were confirmed in more recent extensions of the study [16 ] , although they are not thioprine, could incite or worsen chronic rejection in a few cases. applicable to patients who acquired HCV by transmission at the moment of the transplant. The author tries It is surprising that in our group of HCV+ patients the causes of mortality are not apparently related to to explain this latter finding by the slow-developing course of hepatitis C. Recently, Legendre et al. [15] the hepatitis, but are similar to the general distribution of causes of death in the middle to late post-operative demonstrated worse graft and patient survival for HCV+ recipients in a study on a larger series of period. We could not explain this by a longer duration of the end-stage renal failure ( long-term dialysis of the patients with long periods of follow-up during dialysis and after transplantation. Our results agree with this HCV+ patients resulting in more advanced chronic vascular disease). On the other hand, the HCV+ study with regards to survival, although we did not find evidence of greater mortality due to infection or patients showed worse renal function at middle term and this could have increased the risk of death from liver disease. The demonstration of differences in survival for HCV+ patients is more difficult because of vascular causes. The greater frequency of insulindependent diabetes mellitus among the HCV+ patients the characteristics of these patients (number of transfusions, immunization status, re-transplants) that change [21] is quite relevant for vasculopathies, and has been previously described for liver transplant patients [22] their immunological risk. We believe that we have demonstrated in our group that the presence of pre-and the general population [23] .
Despite the advances achieved in the prevention of or post-transplant antibodies to HCV constitutes a risk factor that does not depend on such con-infection by HCV in countries with previous high prevalence rates of HCV+ in patients on dialysis, this founding data.
The disagreement in results between the transplant factor will continue to be of importance in the coming years. Long-term systematic analyses of large groups centres, excluding those studies with limitations in prognostic indicator in black kidney transplant recipients.
are justified in order to elucidate the influence of Transplantation 1993; 55: 1283 -1287 hepatitis C on transplant survival. 12 . Ihara H, Ikoma F. Influence of anti-hepatitis C virus antibody on kidney transplant survival in a single Japanese center. Transplantation 1994; 57: 781
